GlobeNewswire by notified

iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

Share

October 26, 2023

  • Safety of Philips’ iFR in the guidance of percutaneous coronary intervention (PCI) for heart disease demonstrated in late-breaking science at TCT 2023 highlighting patient-level outcomes analysis of 42,000 patients from the National Swedeheart Quality Registry
  • Previous data demonstrate that iFR delivers consistent patient outcomes, reduces discomfort and offers a more cost-effective and faster diagnostic solution [1,2] compared to FFR

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the latest results demonstrating the safety of Philips instant wave-free ratio (iFR) in the guidance of PCI.

Philips is committed to clinically validating its innovations in cardiac and cardiovascular care. iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures. iFR avoids the use of hyperemic agents, a class of drugs that maximize blood flow but have a significant impact on the patient experience [3].

A longitudinal analysis from the National Swedeheart Quality Registry of more than 42,000 patients undergoing coronary procedures, showed no difference between iFR and fractional flow reserve (FFR) in major adverse cardiac events (MACE) [4]. The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.

“These new findings once again confirm the safety of iFR. We continue to see that iFR-guided treatment offers consistent outcomes, reduces costs, and provides a better patient experience,” said Dr. Götberg, Department of Cardiology, Clinical Sciences, Lund University, Sweden, who presented the results during a late-breaking science session at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco. “The data from this new analysis provides additional confidence in the safety of iFR for physicians.”

In the previously published analysis of the five-year outcomes of the randomized trial iFR-SWEDEHEART, results found iFR and FFR to be equally safe and effective with respect to risks for MACE. The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years). There was no difference in risk for death, heart attack or new revascularization [3].

The results presented today from the SWEDEHEART registry revealed that patients in the iFR group had more risk factors compared with the FFR group but when adjusted for known confounders there was no difference in 5-year MACE between patients who underwent iFR or FFR-guided revascularization (32.2% vs. 31.3%, adjusted HR 0.99, 95%CI 0.93–1.05, p=0.65). Furthermore, the outcome was similar in the individual components of MACE (death, heart attack, new revascularization) as well as in both deferred and treated subgroups.

Patient discomfort can be reduced by 95.7 percent
iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4]. Similar to FFR, clinicians use these tools coupled with angiographic images to assess coronary blockages. However, by avoiding administrating a hyperemic agent, patient discomfort can be reduced by 95.7 percent and enables iFR to detect disease processes downstream from the major blood vessels [4].

Only Philips iFR has a Class IA recommendation by the American College of Cardiology, American Heart Association, Society for Cardiovascular Angiography & Interventions and European Society of Cardiology [1,2].

“We are confident in our pursuit of innovation to improve outcomes and ensure patient safety. The data continues to demonstrate the benefits of iFR-guided treatment to reduce costs and improve outcomes,” said Chris Landon, General Manager, Philips Image Guided Therapy Devices. “iFR technology is unique to Philips, and we are proud to offer the global gold standard treatment for patients with ischemic heart disease.”

For more information on Philips and the iFR data, please visit http://www.philips.com/iFR and follow the #TCT2023 conversation with @PhilipsLiveFrom throughout the event.

[1] Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129.
[2] 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96. Japan guidelines.
[3] Gotberg M, et al. Instantaneous wave-free ratio compared with fractional flow reserve in PCI: A cost-minimization analysis. Int J Cardiol 2021 1;344:54-59.
[4] Gotberg M, Berntorp K, Rylance R, et al. 5 – Year outcomes of PCI guided by measurement of instantaneous wave-free ratio versus fractional flow reserve. J Am Coll Cardiol. 2022;79(10):965–974.

For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel. : +31 6 10558116
E-mail: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 70,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fluence Responds to Misleading Short Seller Report22.2.2024 23:32:54 CET | Press release

ARLINGTON, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence” or “the Company”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and optimization software for renewables and storage, today issued a statement in response to a report published by a known short-seller. The Company believes that the report is an attempt by a self-interested short-seller to profit at the expense of Fluence’s shareholders by manipulating Fluence’s stock price. We believe that the report contains numerous inaccuracies and distortions. The Company believes it is important to set the record straight regarding three blatant misrepresentations: The short-seller's report references pending litigation between Fluence and Siemens Energy, attempting to characterize it as a "critical and dramatic development." While any dispute with a customer is unfortunate, this is a small, ordinary course commercial dispute arising from a single project. Fluence brought the action

Galapagos announces full year 2023 results and outlook for 202422.2.2024 22:01:00 CET | Press release

Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RTExpanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMMEnrolled first patients in Phase 2 study with TYK2 inhibitor, GLPG3667, in DM and SLEFor strategic reasons, it was decided not to continue development of CD19 CAR-T candidate in rSLEExpanded point-of-care CAR-T network in the U.S. with manufacturing agreements with Landmark Bio and Thermo Fisher Scientific Signed strategic research and license collaboration with Brid

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors22.2.2024 19:02:45 CET | Press release

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors. Diane Souza, Member of the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will leave the Board of Directors at the end of their second terms. The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office. The Chairman specified that, in order to prepare as effectively as possible for the end, in 2025, of the term of office as director of F

EVS reports 2023 results22.2.2024 18:30:00 CET | Press release

Publication on February 22, 2024, after market closing Regulated and inside information – Press release annual results EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports 2023 results Liège, Belgium, February 22nd, 2024 EVS further delivers profitable growth in 2023, validating the effectiveness of its PlayForward strategy The robust financial performance of EVS in 2023 underscores the effectiveness of the implemented strategy aimed at fostering sustained and profitable long-term growth. Despite the absence of significant Big Event Rental revenue in an uneven year 2023, EVS achieved record-breaking revenue and demonstrated strong profitability. This success serves as a testament to the efficacy of its PlayForward strategy. Full-year Highlights Order intake outpacing revenue at EUR 192.9 million, including EUR 7.4 million of Big Event Rental (BER).Revenue performance landing north of our guidance at EUR 173.2 million, growing 16.9%

RevoluGROUP Canada Inc. Issues Incentive Share Options22.2.2024 18:23:23 CET | Press release

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces that incentive share options to purchase up to 5,200,000 common shares of the Company were granted to consultants and Directors of the Company, with an exercise price of $0.05 per share. The incentive share options have been granted pursuant to the Company's 10% rolling stock option plan and will expire twenty-four months from the grant date. Should all announced options be exercised in the term, the aggregate amount payable to the treasury would be CA $ 260,000. The options are to be granted as shown below: Francisco Moreno Balboa1,500,000Gavin McMillan500,000Bernard Lonis500,000Alfredo Manresa Ruiz500,000Fernando Guillen Hernandez500,000 An additional 1,700,000 options were also granted to consultants in the Company who have provided valuable assistance in the development of products, business development, solution integra

HiddenA line styled icon from Orion Icon Library.Eye